SCHEMBL6095962

SCHEMBL6095962

Cc1nc(N)c2ncn(CCCCNC(=O)c3ccc(C(OCCN(C)C)c4ccccc4)cc3)c2c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.37
DRD3 P35462 4/20 0.37
CHRM2 P08172 3/20 0.37
ADRA2A P08913 3/20 0.37
CHRM1 P11229 3/20 0.37
SLC6A2 P23975 3/20 0.37
SLC6A3 Q01959 3/20 0.37
HTR2A P28223 3/20 0.37
SLC6A4 P31645 2/20 0.37
OPRM1 P35372 2/20 0.37
CYP1A2 P05177 2/20 0.37
CHRM4 P08173 2/20 0.37
CHRM5 P08912 2/20 0.37
CYP2D6 P10635 2/20 0.37
ADRA2B P18089 2/20 0.37
CHRM3 P20309 2/20 0.37
HTR2C P28335 2/20 0.37
HRH1 P35367 2/20 0.37
HTR2B P41595 2/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8133004 0.90 TLR7 (0.44) LMNADRD3CHRM2ADRA2ACHRM1
SCHEMBL8125963 0.89 TLR7 (0.45) LMNADRD3CHRM2ADRA2ACHRM1
SCHEMBL8128022 0.87 TLR7 (0.44) LMNAHTR2AHTR2BHRH2ADRA1A
SCHEMBL6093743 0.84 TLR7 (0.50) TLR7
SCHEMBL6768483 0.84 DRD3 (0.44) LMNADRD3HTR2ACYP1A2CYP2D6
SCHEMBL8134654 0.83 TLR7 (0.42) LMNAHTR2AHTR2BHRH2ADRA1A
SCHEMBL8125486 0.79 TLR7 (0.49) TLR7
SCHEMBL6774052 0.79 POLB (0.43) DRD3ADRA1AHTR1ADRD2DRD4
SCHEMBL8127086 0.78 TLR7 (0.41) LMNASLC6A2SLC6A3HTR2ASLC6A4
SCHEMBL6773548 0.78 HDAC3 (0.49) LMNADRD3ADRA2ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040186128-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-23 US claimed
EP-1451187-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-01 EP claimed
US-20030186949-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-02 US claimed
US-20030162806-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-28 US claimed
WO-2003050118-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO claimed
US-6545016-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 US claimed
US-7098221-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-08-29 US disclosed
US-20050282854-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2005-12-22 US disclosed
US-6969722-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-11-29 US disclosed
US-20040186128-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-23 US disclosed
EP-1451187-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-01 EP disclosed
US-6720422-B2 MODULATORS OF IMMUNE RESPONSE BY INDUCTION OF CYTOKINE BIOSYNTHESIS; SUBSTITUTED 4-PHENOXY-IMIDAZO(4,5-C)PYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2004-04-13 US disclosed
US-6720333-B2 IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; N-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)BENZAMIDE 3M INNOVATIVE PROPERTIES COMPANY 2004-04-13 US disclosed
US-20030186949-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-10-02 US disclosed
US-20030162806-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-28 US disclosed
WO-2003050118-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
US-6545016-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186128-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG LMNA 4648/4885DRD3 4776/4885CHRM2 3865/4885
US-20050282854-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG LMNA 4648/4885DRD3 4776/4885CHRM2 3865/4885
US-20030162806-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG LMNA 4648/4885DRD3 4776/4885CHRM2 3865/4885
US-20030186949-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG LMNA 4648/4885DRD3 4776/4885CHRM2 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.